What is Until Labs?
Until Labs operates at the vanguard of biological engineering, focusing on the development of advanced cryopreservation methodologies. By integrating expertise from diverse scientific disciplines, the company seeks to address fundamental challenges in cellular preservation and biological stasis. Its market position is defined by a commitment to high-barrier-to-entry research, targeting long-term solutions that could redefine human health and biological longevity. The company's internal structure, which bridges the gap between theoretical physics and applied biology, allows it to maintain a competitive edge in a highly specialized niche.
How much funding has Until Labs raised?
Until Labs has raised a total of $58M across 1 funding round:
Series A
$58M
Series A (2025): $58M with participation from Founders Fund and Lux Capital
Key Investors in Until Labs
Founders Fund
Founders Fund is a prominent venture capital firm known for backing transformative companies across various sectors, with a focus on high-impact, founder-led enterprises.
Lux Capital
Lux Capital specializes in early-stage and growth-stage investments at the intersection of science and technology, particularly in frontier areas like biotechnology and advanced materials.
What's next for Until Labs?
Looking ahead, the strategic deployment of the $58M will likely focus on expanding laboratory capacity and accelerating the commercialization of its core technology. As the company moves beyond its initial development phase, the focus will shift toward regulatory milestones and the refinement of its cryopreservation protocols. Investors are closely monitoring the firm's ability to translate complex scientific breakthroughs into viable, enterprise-grade solutions. The current funding environment suggests that Until Labs is well-equipped to navigate the complexities of the biotech landscape, potentially setting the stage for future growth and industry-wide adoption of its proprietary methods.
See full Until Labs company page
